Sensodyne shines for GSK but Lucozade is off-colour

  • Print
  • Share
  • Comment
  • Save

Toothpaste and smoking quitting aids helped drive growth at the consumer healthcare arm of GlaxoSmithKline over the past three months.

Sales in the consumer healthcare division were up 5% in the past three months to £1.33bn, driven by strong growth for the oral healthcare business, up 10%, and the Sensodyne brand in particular.

Nutritional healthcare was up 9% thanks to the Maxinutrition acquisition earlier this year, while sales of Lucozade took a hit from increased activity by rival brands.

Sales of over-the-counter medicines, where GSK owns brands including Beechams, Gaviscon and Nytol, were flat for the period.

Meanwhile, GSK warned that the impact of forced price cuts on pharmaceuticals in Europe and the US could cost it as much as £325m for the full year. Sales across the business, including its pharmaceutical and vaccines divisions, were up 4% for the three-month period to £7.1bn.

Have your say

You must sign in to make a comment

Related images

  • Print
  • Share
  • Comment
  • Save

Grocer jobs Experts in FMCG

Weetabix c/o SmithCarey HEAD of REVENUE MANAGEMENT

HEAD of REVENUE MANAGEMENT - Weetabix c/o SmithCarey

Highly competitive, bonus, car or allowance & benefits
Search jobs
Sign in

Newsletter Sign-up


I wish to receive the following newsletters:

For Members

Become a Gold Member to receive these newsletters:

Become a Finance Member to receive these newsletters:

Become a member of The Grocer



CLICK HERE to search for the products, services and companies you need in the definitive guide to the UK food and drink industry.


The Grocer's commentators and opinion makers